RecruitingNCT04798690

Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature

Open, Multi-center, Non-interventional, Prospective/ Retrospective Observational Study on Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature

Sponsor

Dong-A ST Co., Ltd.

Enrollment

5,000 participants

Start Date

Feb 8, 2021

Study Type

OBSERVATIONAL

Conditions

Turner Syndrome Growth Hormone Deficiency Small for Gestational Age Idiopathic Short Stature

Summary

This study evaluates long-term safety and effectiveness of Growtropin®-II treatment in children with short stature.

Eligibility

Min Age: 2 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with growth hormone deficiency, idiopathic short stature, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 2 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.